Boryung Corp. secured a manufacturing deal with Taiwan’s Lotus Pharmaceutical Co. to produce injectable cancer treatments, expanding its presence in Asia’s pharmaceutical contract services market.
The South Korean pharmaceutical company will start manufacturing the undisclosed anticancer drug at its Yesan plant in 2026, according to a company statement Thursday. The facility, located in South Chungcheong Province, was designed by Novo Nordisk Engineering and has an annual production capacity of 6 million vials.
The agreement marks Boryung’s latest push to boost its contract development and manufacturing organization business for cytotoxic drugs, capitalizing on growing demand for outsourced pharmaceutical production in Asia. The deal could help offset rising operational costs that have squeezed margins at many regional drugmakers.
The EU-GMP certification of Boryung’s facility positions the company to potentially capture more international contracts, as regulatory compliance becomes increasingly important for pharmaceutical manufacturing. Neither company disclosed the financial terms of the agreement.
Lotus Pharmaceutical, which specializes in oncology treatments, has been expanding its product portfolio through partnerships across Asia. The collaboration with Boryung aligns with its strategy to secure reliable manufacturing partners for its growing pipeline of cancer therapies.
